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sequelae) are added using the differences between survivor curves
of Hepatitis B infected persons and population survivor curves.
RESULTS: Without the inclusion of future unrelated medical
costs, Hepatitis B vaccination costs €900 per life year gained.
Adjusting the ICER for these costs results in an increase to
approximately €5.700 per life year gained. CONCLUSIONS: We
conclude that the adjusted ICER provides more evidence-based
and transparant information about the real cost-effectiveness of
an intervention.
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OBJECTIVES: Several estimators exist when average utility
scores are not available for patient populations with multiple
disease conditions. The multiplicative estimator is a widespread
choice among them. Our study is to empirically test the accuracy
of the multiplicative estimator and compare it with other estima-
tors. METHODS: The Medical Expenditure Panel Survey
(MEPS) has a nationally representative sample of the US civilian
non-institutionalized population. Using the pooled 2001 and
2003 data, a sample of 40,846 individuals with EQ-5D index
scores were categorized into 238 disease condition categories.
The study focus was the difference between the estimated and the
observed mean scores for each comorbid pair, with the observed
one presumed to be the true value. RESULTS: The scores esti-
mated by multiplying the two mean scores of the corresponding
disease conditions on average had a statistically signiﬁcantly
larger difference (p < 0.0001) from the observed ones (-0.094)
than simply picking the smaller mean of the two paired condi-
tions (difference = 0.025), the larger mean of the two (differ-
ence = 0.071), the average of the two means (difference = 0.048),
or the mean of the condition with smaller sample size of the pair
(difference = 0.049). However, the multiplicative estimator per-
formed better than the additive estimator (sum of the means
minus 1, difference = 0.123). CONCLUSIONS: Multiplication is
not a good estimate when the average utility score for patients
with two disease conditions is not readily available. The lower of
the two utility scores had the least error among those estimators
that we compared. Further research with an experimental
design is warranted before a speciﬁc alternative can be ﬁrmly
recommended.
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OBJECTIVES: Despite the increased use of generic medicines,
little is known about patients’ attitudes towards them and
patients’ decision-making process of the medicine purchased.
The aim of the study is to assess the patients’ preference struc-
ture for generic and branded over-the-counter (OTC) pain medi-
cines and their price elasticity. METHODS: Finnish university
students (n = 209) responded to an adaptive conjoint analysis
(ACA) interview. Product attributes of price, brand, onset time
of effect, place of purchase and source of information were
included on the basis of the literature, a focus group and a pilot
study. The descriptors of the respondents included socioeco-
nomic background, involvement with the purchase process, and
health behavior. Individual-level utility functions were esti-
mated, preference clusters identiﬁed, and price elasticity of the
generic medicine estimated. RESULTS: Brand and price were
the most important attributes. Even in the homogenous target
group, ﬁve clusters with characteristic preferences, price elastic-
ity and socioeconomics background were detected. Approxi-
mately half of the respondents were strongly price sensitive.
Among all the respondents, the price elasticity of a generic OTC
medicine was from -1.34 to -0.69 at the discount range of
20–60%. Even positive price elasticity was detected. In the clus-
ters with negative price elasticity, discount of 4–42% were
required to make the generic medicine equally preferred with
the branded one. In comparison with the results of our corre-
sponding study conducted before the launch of generic substi-
tution leading to common interest in generic medicines and
medicine costs in Finland, patients’ awareness of generic medi-
cines had increased, attitudes towards them were more favor-
able, and they seemed to purchase OTC medicines more
independently. CONCLUSIONS: The study provided novel
information on the concomitant effects of brand, price and
other essential product attributes on the patients’ choice of an
OTC medicine. ACA proved to be a useful tool in the research
of patients’ and patient groups’ preferences.
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OBJECTIVES: Investigate Greek adults’ perceptions of drug
effectiveness and prices. METHODS: A structured questionnaire
was used in a telephone survey in order to derive data from a
national random sample of 1000 adults, stratiﬁed by age, gender
and geographic region. Physicians and pharmacists were
excluded from the sample. The study was conducted in June
2007. The response rate was 93.0%. RESULTS: Drugs were
considered by the majority of respondents (75.7%) as safe and
effective as well as very important for medical practice (65.2%).
Respondents believed that new drugs are of a higher price
(67.8%), however these were perceived as more effective than
older ones (79.4%) Regarding the prices of drugs in Greece, one
out of two respondents believed that the prices are extremely
high. Women as opposed to men expressed the less positive
opinion on the implemented pricing policy. The majority of
respondents (81.4%) recognized that the cost of R&D should be
included into the price of the drugs, but they think that the
pricing regulation of drugs is in favor of pharmaceutical indus-
tries (90.1%). Furthermore, they expressed the opinion that
prices should be as low as possible regardless of the effectiveness.
On the other hand, they claimed that physicians should always
prescribe the most effective drug regardless of its price. The
majority of respondents (89.4%) reported that polypharmacy
and irrational prescribing are major problems in Greece and
considered doctors to be primarily responsible, followed by the
absence of audit in the health system. CONCLUSIONS: Despite
the fact that drugs prices are considered high, Greek adults have
a strong positive view regarding their safety and effectiveness.
Knowledge on both the public’s perception regarding drugs and
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